10 Nov 2026
byJairia Dela Cruz
Biweekly or 14-day dosing of trifluridine–tipiracil (FTD–TPI) plus bevacizumab is noninferior to the conventional 28-day dosing schedule, with similar survival outcomes but reduced haematological and gastrointestinal toxicity in metastatic colorectal cancer (mCRC), according to the pragmatic phase III PRABITAS trial with broad eligibility criteria.